MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

3.170
+0.280
+9.69%
Pre Market: 3.800 +0.63 +19.87% 09:17 08/14 EDT
OPEN
2.900
PREV CLOSE
2.890
HIGH
3.230
LOW
2.850
VOLUME
72.80K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
0.4900
MARKET CAP
82.59M
P/E (TTM)
-4.5618
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NAVB stock price target is 5.00 with a high estimate of 6.00 and a low estimate of 4.000.

EPS

NAVB News

More
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13)
Benzinga · 52m ago
Navidea Biopharmaceuticals stock price target raised to $7 from $4 at Maxim Group
NAVB | Complete Navidea Biopharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 1h ago
Navidea Biopharm EPS misses by $0.01, misses on revenue
Navidea Biopharm (NAVB): Q2 GAAP EPS of -$0.11 misses by $0.01.Revenue of $0.27M (+3.8% Y/Y) misses by $0.33M.Press Release
Seekingalpha · 17h ago
Navidea Biopharm EPS misses by $0.01, misses on revenue
Navidea Biopharm (NAVB): Q2 GAAP EPS of -$0.11 misses by $0.01.Revenue of $0.27M (+3.8% Y/Y) misses by $0.33M.Press Release
Seekingalpha · 17h ago
Navidea Biopharm EPS misses by $0.01, misses on revenue
Navidea Biopharm (NAVB): Q2 GAAP EPS of -$0.11 misses by $0.01.Revenue of $0.27M (+3.8% Y/Y) misses by $0.33M.Press Release
Seekingalpha · 17h ago
Navidea Biopharmaceutical Q2 EPS $(0.11) Up From $(0.24) YoY, Sales $271.00K Beat $156.00K Estimate
Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.11) per share. This is a 54.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly
Benzinga · 17h ago
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 1d ago
Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.09% to 27734 while the NASDAQ fell 0.45% to 10961.67. The S&P also rose, gaining 0.17% to 3,356.99.
Benzinga · 3d ago

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About NAVB

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.
More

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.